MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/opth.s622037

Медицинская библиотека · Clinical ophthalmology (Auckland, N.Z.) · 2026

Visual Gains with Faricimab vs Aflibercept 8 mg in Naïve Retinovascular Disease: Global Real-World Cases and Literature Review.

Mansour Hana A, Eandi Chiara M, Pichi Francesco, Foster Robert E, Charbaji Suzanne A, Chakraborty Debdulal, Ellabban Abdallah A, Belotto Silvana, Abu Serhan Hashem, Magnin Simon, Lopez-Guajardo Lorenzo, Pérez-Salvador García Eduardo, Schwartz Stephen G, Stewart Michael W, Rey Amanda, Jürgens Ignasi, Casella Antonio M B, Upadhyay Anubhav, Sheth Jay U, Lima Luiz H, Sinawat Suthasinee, Abengoechea Santiago, Capella Maria Jose, Viver Oller Sonia, Elizalde Javier, Kheir Wajiha J, Mammo Danny, Barbosa Gabriel Castilho Sandoval, Villegas Victor M, Desai Arjun, Tripathy Koushik, Bala Suraj, Mohan Nitesh, Elnahry Ayman G, Uwaydat Sami H, Cherfan Daniel G, Parodi Maurizio Battaglia, Mansour Ahmad M

СтатьяПеревод в очереди

Аннотация

BACKGROUND

To compare the visual gains of faricimab and aflibercept 8 mg as first-line in real-world management of retinovascular diseases.

METHODS

Retrospective multicenter interventional case series with retinovascular diseases initiated on faricimab or aflibercept 8 mg till August 30, 2025. Main outcome measure was visual gain in logMAR. Linear mixed-effects model was used to compare vision increase between the two drug groups. In addition, comparative Phase 3 trials were supplemented by a literature review of treatment-naïve eyes using major databases till September 30, 2025.

RESULTS

We collected 500 treated eyes from 35 collaborating centers. The treatment groups included 395 eyes receiving faricimab vs 105 receiving aflibercept 8 mg distributed into neovascular macular degeneration (270 vs 58), diabetic macular edema (97 vs 39) and macular edema associated with retinal vein occlusion (28 vs 8). Adjusted visual gains were comparable between the two drugs in various retinal categories (p=0.672).

CONCLUSION

Visual acuity improved significantly and equally in both aflibercept 8 mg and faricimab in several treatment-naïve retinovascular diseases.

Для цитирования: Mansour Hana A, Eandi Chiara M, Pichi Francesco, Foster Robert E, Charbaji Suzanne A, Chakraborty Debdulal, Ellabban Abdallah A, Belotto Silvana, Abu Serhan Hashem, Magnin Simon, Lopez-Guajardo Lorenzo, Pérez-Salvador García Eduardo, Schwartz Stephen G, Stewart Michael W, Rey Amanda, Jürgens Ignasi, Casella Antonio M B, Upadhyay Anubhav, Sheth Jay U, Lima Luiz H, Sinawat Suthasinee, Abengoechea Santiago, Capella Maria Jose, Viver Oller Sonia, Elizalde Javier, Kheir Wajiha J, Mammo Danny, Barbosa Gabriel Castilho Sandoval, Villegas Victor M, Desai Arjun, Tripathy Koushik, Bala Suraj, Mohan Nitesh, Elnahry Ayman G, Uwaydat Sami H, Cherfan Daniel G, Parodi Maurizio Battaglia, Mansour Ahmad M. Visual Gains with Faricimab vs Aflibercept 8 mg in Naïve Retinovascular Disease: Global Real-World Cases and Literature Review.. Clinical ophthalmology (Auckland, N.Z.). 2026. DOI: 10.2147/opth.s622037.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.